Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Change in Accured Expenses: 2011-2024

Historic Change in Accured Expenses for Abeona Therapeutics (ABEO) over the last 9 years, with Dec 2024 value amounting to $1.5 million.

  • Abeona Therapeutics' Change in Accured Expenses rose 1367.09% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 271.55%. This contributed to the annual value of $1.5 million for FY2024, which is 26.16% down from last year.
  • According to the latest figures from FY2024, Abeona Therapeutics' Change in Accured Expenses is $1.5 million, which was down 26.16% from $2.0 million recorded in FY2023.
  • In the past 5 years, Abeona Therapeutics' Change in Accured Expenses registered a high of $2.0 million during FY2023, and its lowest value of -$4.1 million during FY2022.
  • Its 3-year average for Change in Accured Expenses is -$186,667, with a median of $1.5 million in 2024.
  • In the last 5 years, Abeona Therapeutics' Change in Accured Expenses slumped by 597.94% in 2022 and then spiked by 149.68% in 2023.
  • Abeona Therapeutics' Change in Accured Expenses (Yearly) stood at $825,000 in 2021, then plummeted by 597.94% to -$4.1 million in 2022, then spiked by 149.68% to $2.0 million in 2023, then dropped by 26.16% to $1.5 million in 2024.